Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has filed a Prospectus Supplement No. 5 to incorporate information from their Form 6-K dated June 27, 2025. The filing covers the resale of 2,486,190,000 ordinary shares (representing 248,619 American Depositary Shares) by selling shareholders.
Key highlights:
- All resolutions at the Annual General Meeting held on June 26, 2025, were successfully passed
- Last reported closing price of ADSs was $0.9215 on NASDAQ Capital Market
- Company's pipeline includes three main development programs: - eRapa: For Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer - Tolimidone: For type 1 diabetes treatment - MTX110: For aggressive rare/orphan brain cancer indications
The company leverages three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of medicines, with headquarters and R&D facility in Cardiff, UK.
Biodexa Pharmaceuticals has filed a prospectus supplement related to the potential resale of 341,352,000,000 ordinary shares (representing 34,135,200 American Depositary Shares). The company's ADSs trade on NASDAQ under symbol BDRX, with a last reported closing price of $0.9215 on June 26, 2025.
The filing also includes Form 6-K reporting the results of their Annual General Meeting held on June 26, 2025, where all proposed resolutions were passed. The company is advancing several key drug development programs:
- eRapa - An oral rapamycin formulation for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer
- Tolimidone - A Lyn kinase inhibitor for type 1 diabetes treatment
- MTX110 - A panobinostat formulation for rare/orphan brain cancers
The company leverages three proprietary drug delivery technologies to improve bio-delivery and bio-distribution of medicines. Their R&D facility is located in Cardiff, UK.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) filed a Form 6-K to report the outcome of its 26 June 2025 Annual General Meeting. The company confirms that every resolution listed in the 23 May 2025 AGM notice was duly approved by shareholders. Although the filing does not enumerate the resolutions or voting percentages, management notes that the results have been incorporated by reference into its effective registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-267932), thereby keeping those shelf offerings current.
A related press release dated 27 June 2025 (Exhibit 99.1) reiterates the successful passage of all motions. The press release is furnished—not filed—under the Exchange Act, limiting potential liability under Section 18.
No financial statements, earnings data, or strategic transaction details were included. The disclosure is largely procedural, aimed at satisfying SEC requirements and informing investors that corporate authorisations—potentially covering director re-elections, auditor appointment, remuneration, and share-issuance mandates—remain in force.